Concepedia

Author

Armelle Vinceneux

Centre Léon BérardORCID

Also Known As

A Vinceneux, A. Vinceneux, Armelle Vinceneux, Benjamin Verret

60

Publications

434

Citations

10

H-Index

18

Concepts

All Affiliations

Centre Léon BérardInstitut Gustave RoussyInstitut Claudius RegaudCentre Hospitalier Universitaire de ToursInstitut Jules Bordet
AV

About

Armelle Vinceneux is an author at Centre Léon Bérard specializing in cancer research, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

113

2

Immunology

1

1

25

3

Obstetrics

1

1

36

4

Pathology

1

1

52

5

Pharmacology

1

1

25

Armelle Vinceneux

×

8

Publications

197

Citations

8

H-Index

YearCitations

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Loïc Lebellec, Bruno Chauffert, Jean‐Yves Blay,

European Journal of Cancer

2017

52

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

Anne Ploquin, B. Pistilli, Emmanuelle Tresch,

European Journal of Cancer

2018

36

Ductal adenocarcinoma of the prostate: Clinical and biological profiles

Armelle Vinceneux, F. Bruyère, O. Haillot,

The Prostate

2017

33

Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.

Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki,

Journal of Clinical Oncology

2021

25

A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)

David Kryza, Armelle Vinceneux, Anne-Sophie Bidaux,

BMC Cancer

2024

16

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Mark N. Stein, Armelle Vinceneux, Debbie Robbrecht,

Journal of Clinical Oncology

2025

14

983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

Nuria Kotecki, Stéphane Champiat, J.P. Delord,

Annals of Oncology

2021

11

Patients’ selection and trial matching in early-phase oncology clinical trials

Pauline Corbaux, A. Bayle, Sylvain Besle,

Critical Reviews in Oncology/Hematology

2024

10

Page 1